Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. Full study results: https://t.co/C5oIChPFbG
Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation https://t.co/Ja8nORGjYr
1/ A resident asked me how to interpret the two UC guselkumab trials
Same drug (IV/SC induction). Different trial designs, denominators & clinical meaning!
QUASAR = responder re-randomization
ASTRO = randomized treat-through
✅ key lesson: before comparing numbers, understand the design
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO
#CGH4ALL@AGA_CGH
📣 Exciting data in #EoE: A potential step toward restoring dietary freedom while maintaining disease control in EoE.
🔹Open-label pilot study, patients (6–25 yrs) w/ milk/egg/soy/wheat-triggered EoE
🔹Dupilumab for 3 months, followed by stepwise food reintroduction up to 12 months
🔹All completers successfully reintroduced ≥1 trigger food, and many expanded diets every 3 months
#GITwitter #MedTwitter
🔗https://t.co/dManUlSOps
Reported by @AasthaBharwad@EdoardoSavarino, @NdeBortoli, @SebastianZeki, @stevenbollipo, @DrCJudge, @my_ueg, @virgisolitano, @eathar_s, @DaniyalAbbasMD
🌍¡Comienza la cuenta atrás! El 22 de mayo es el Día Mundial de la EoE 2026. 🎗️La esofagitis eosinofílica afecta a miles de personas, pero que sigue siendo invisible para muchos. Es hora de unir nuestras voces para apoyar. No te pierdas el video oficial https://t.co/2gJoP5ugcc
Rewarding to see our @HabermanLab study featured on the cover, laying the conceptual framework to underlying mechanism of escape from AT remission (=flare) d/t persistent dietary-metabolic gut perturbances. Hence the need for combined AT-nutrition trials
@HelmsleyTrust
A new article summarizes the epidemiology, diagnosis, and management of celiac disease and highlights serologic testing, biopsy confirmation, associated autoimmune conditions, and a gluten-free diet as treatment.
Read the Clinical Practice article “Celiac Disease” by Joseph A. Murray, MD, and Steffen Husby, MD, DMSc, from @mayoclinic and the University of Southern Denmark: https://t.co/mK3xminnKI
New research - Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
https://t.co/WhBmg8MWfW
#GITwitter
Do LLMs change their ethics based on who the patient is?
Our new paper in @JAMANetworkOpen suggests they can.
Such biases may shape #GI decision-making. It challenges the validity and equity of AI-supported clinical practice.
@UriKopylov@EyalKlang
https://t.co/auKF859yQF
זה אחד הדברים ההזויים. בגלל ש-70-40 אחוז מאמהות לילדים עם אוטיזם - מאמינות שחיסון גרם לאוטיזם - אז זה אומר שזה נכון. לא מחקר ולא כלום. אמונה. אנחנו גמורים בריבוע
New publication!
Our study shows that CADe introduction did not improve surveillance colonoscopy performance in #IBD patients.
Highlights the need for IBD-specific CADe tools & attention to physician-AI dynamics.
https://t.co/PSi3KWDJ7h
@IBDJournals@UriKopylov@ShomronH
Comparative Safety of JAKi vs AntiTNF in IMIDs SR&MA
➡️ 42 studies
🧑🤝🧑813,881 patients
Congratulations @virgisolitano@vipuljairath and rest of authors
https://t.co/91PBrrh3pk
Proud to share the first #ECCO Consensus on Dietary Management of #IBD! 30+ experts & patient voices united to turn diet into therapy.
https://t.co/oPtc6s5ZON
Huge thanks to the incredible multidisciplinary team 🌍🙏 #Crohns#Colitis#DietMatters